|
|
New This Month!
We are pleased to release a new and improved RheumatologyWeb. Much that has changed will be transparent to you, but you will
notice that the login/logout process has been updated (look for your name in the top left corner after you log in). Speaking of your name, please be
sure to update your preferences after you log in.
We are most excited about our new content, including two new CME courses that showcase our new CME engine.
We are still in the process of carrying over the content from the previous incarnation of RheumatologyWeb, so you may notice that certain areas
of the site are empty. We are working as quickly as possible to bring everything back! In the meantime, make sure you don't miss these:
Current Articles
The past year has been marked by steady progress in our understanding of rheumatic diseases, leading to ever-more
efficacious therapeutic strategies. The RheumatologyWeb Editorial Board in conjunction with Tufts University School of Medicine is pleased
to present this series of case-based reviews that will help demonstrate recent advances in the treatment of rheumatic conditions.
Provides up to 3 credit hours of category 1 credit.
The past year has been marked by striking progress in our understanding of the pathogenesis and underpinnings of pain
syndromes, leading to ever-more efficacious therapeutic strategies. The PainManagementWeb Editorial Board in conjunction with Tufts University
School of Medicine is pleased to present this series of case-based reviews that will help demonstrate recent advances in the treatment of pain
syndromes. Provides up to 3 credit hours of category 1 credit. Offered in cooperation with our sister site
PainManagementWeb.
Are glucosamine and chondroitin supplements for osteoarthritis safe in Type 2 diabetics? Yes,
Larry Moreland, M.D., reports in this Literature Review, but an upcoming NIH trial will provide
definitive answers.
Are intraarticular steroids equivalent to hyaluronic acid injections for osteoarthritis?
Yes, according to a new report, Carlos J. Lozada, M.D., notes in this Literature Review, but study
weaknesses still leave the question in doubt.
A 38-year-old African American woman presents with a four-month history of symmetrical polyarthritis.
What are her treatment options? Therapy can include a combination of medications, reports Larry Moreland, M.D.,
in this Hot Issue, a comprehensive review of recent developments in rheumatoid arthritis.
Should physicians pay more attention to the "placebo" effect and make use of it in our practice? Although
such an approach goes against our scientific principles, the benefits to patients should not go unnoticed, notes Thomas
J. Schnitzer, M.D., Ph.D., in this Literature Review.
Can a COX-2 inhibitor yield equal benefits - but fewer adverse events - than indomethacin in acute gout
attacks? Yes, reports Larry Moreland, M.D., in this Literature Review. But it's not available in the U.S.
|
|